Tirzepatide vs Semaglutide: What's the Real Difference?

Tirzepatide and semaglutide are both injectable-first GLP-1-based medications, but they work through different mechanisms: semaglutide (Ozempic, Wegovy, Rybelsus) acts on one receptor, GLP-1, while tirzepatide (Mounjaro, Zepbound) acts on two, GLP-1 and GIP. That’s the short version of tirzepatide vs semaglutide — here’s what the difference actually means for how each drug is taken, what it’s approved for, and where the real distinctions are, without inventing a head-to-head efficacy number that no single trial has produced.

What each drug actually is

Semaglutide is a GLP-1 receptor agonist — it mimics the naturally occurring hormone GLP-1 (glucagon-like peptide-1), which affects insulin release, appetite, and how quickly the stomach empties. Per MedlinePlus, semaglutide is sold under three brand names depending on form and approved use: Ozempic and Wegovy (both subcutaneous injections) and Rybelsus (an oral tablet).

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it mimics two hormones, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), instead of one. Per MedlinePlus, tirzepatide is sold under two brand names: Mounjaro and Zepbound, both subcutaneous injections.

That two-receptor-vs-one-receptor distinction is the core mechanistic difference between the two drugs. It’s a separate question from how effective either one is — trial results for each are specific to that drug, dose, and study population, and this article won’t collapse them into a single comparison number. If you’re weighing a small-molecule oral GLP-1 instead of either of these injectables, Orforglipron vs Tirzepatide covers that separate comparison.

Brand names and what each is approved for

	Tirzepatide	Semaglutide
Receptor mechanism	Dual GIP + GLP-1 receptor agonist	GLP-1 receptor agonist only
Brand for type 2 diabetes	Mounjaro	Ozempic (injection), Rybelsus (oral)
Brand for chronic weight management	Zepbound	Wegovy
Form(s) available	Subcutaneous injection only	Subcutaneous injection (Ozempic, Wegovy) or oral tablet (Rybelsus)
Dosing frequency	Once weekly	Once weekly (injection) or once daily (Rybelsus)

Sources: MedlinePlus drug information pages for tirzepatide and semaglutide, linked below.

Notice that tirzepatide has no oral form — every brand of tirzepatide is an injection. Semaglutide is the only one of the two molecules with an FDA-approved oral option (Rybelsus), though that oral form comes with strict administration rules covered in How to Take Rybelsus.

How they’re dosed and taken

Both drugs are injected subcutaneously once weekly when in injectable form — there’s no daily-injection version of either. The specific starting dose, titration schedule, and maintenance dose differ by brand and indication, and both are typically titrated upward gradually to reduce gastrointestinal side effects; your prescriber sets and adjusts that schedule based on your response.

Rybelsus, semaglutide’s oral tablet, is the outlier: it’s taken once daily, on an empty stomach, with no more than 4 oz of plain water, at least 30 minutes before the day’s first food, drink, or other oral medications, per MedlinePlus. Tirzepatide has no equivalent oral version, so this timing restriction doesn’t apply to it at all. For a broader look at how injectable and oral GLP-1 routines differ in general, see GLP-1 Pill vs Injection: What’s Actually Different.

Side effects: same class, similar pattern

Per MedlinePlus drug information for both tirzepatide and semaglutide, the most commonly reported side effects for each are gastrointestinal: nausea, vomiting, diarrhea, and constipation, particularly during dose increases. These effects are shared across GLP-1-based medications as a drug class generally, whether the mechanism is single-receptor (semaglutide) or dual-receptor (tirzepatide). Rates and individual experience vary, and only your prescriber can tell you what’s typical to expect at your specific dose and how to manage it.

What this article won’t claim: a head-to-head efficacy number

You’ll see plenty of claims online about which drug produces more weight loss or better blood-sugar control. This article deliberately doesn’t put a percentage on that comparison. Each drug’s efficacy data comes from its own separate clinical trials, run in different populations at different doses — treating those as directly comparable numbers isn’t the same as a controlled head-to-head study, and presenting them that way would overstate what’s actually been proven. If efficacy is the deciding factor for you, ask your prescriber to walk through each drug’s actual trial results and how they might apply to your situation.

Where orforglipron fits in

Neither tirzepatide nor semaglutide’s injectable forms are the same as orforglipron (Foundayo), a small-molecule oral GLP-1 receptor agonist with once-daily dosing and no food or water restrictions. Orforglipron shares semaglutide’s single-receptor GLP-1 mechanism rather than tirzepatide’s dual-receptor approach. If you’re comparing the full landscape of oral options, Oral GLP-1 Pills: The Full List rounds up what’s currently available in pill form.

Bottom line

Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy, Rybelsus) both belong to the GLP-1 family of medications, but they aren’t interchangeable: tirzepatide is a dual GIP/GLP-1 receptor agonist available only as an injection, while semaglutide is a single-receptor GLP-1 agonist available as both an injection and — via Rybelsus — an oral tablet. Their side-effect profiles are broadly similar, dominated by gastrointestinal symptoms common to the drug class. Which one is right for a given person, and how each performs on weight loss or blood sugar, is a question for a prescriber who can review the specific trial data and your health history — not a single “X% vs Y%” number this article will manufacture.